NanoMedTrix

NanoMedTrix, LLC (often shortened to NMTx) is a privately held American biotechnology company based in Coralville, Iowa, that develops and manufactures engineered nanoparticles for medical applications. According to the company, it was created in 2012 as a spin-off of research conducted by Dr. Assouline at the University of Iowa together with the National Institutes of Health (NIH) and its National Institute of Neurological Disorders and Stroke (NINDS). The stated end goal is to build a clinical-stage oncology and curative enterprise around a nanoscale particle platform technology. The company's core technology is a family of multi-modal, targeted contrast agents it calls MSNs. Contrast agents are co-crystalized inside the particles so that they become uniquely visible across several imaging modalities — ultrasound/echo, MRI, CT and fluorescence — which the company argues can make clinical trials faster and cheaper by increasing discriminate visibility, accuracy and intensity. The particles are intentionally manufactured with void space, allowing them to carry payloads of diverse bioactive substances. Through surface modifications, the targeted particles are designed to impart specificity of the loaded cargo to tumor and cancer cells, thereby sparing non-cancerous, normal tissue from the toxicity associated with traditional systemic treatments. NanoMedTrix positions its platform as theragnostic, meaning it combines therapy and diagnosis in a single approach. In cancer, the company states that its material has been designed to target solid tumors such as bladder, colorectal and neural tumors, and that the same nano-compounds can be adjusted to provide information on the disease process of a multitude of illnesses. Bladder cancer is highlighted as a disease that can benefit from nanotechnology-based treatment because the particles are able to reach muscle-invaded layers. The company has reported preclinical work in mouse, rat and dog models, including an ultrasound (HRS) image of a mouse animal model of bladder cancer in which a tumor treated with a particle-drug combination disappeared. Beyond its core business of nanoparticle development and manufacturing, NanoMedTrix offers services to the scientific community, including patent-pending multi-scale tools for research into early detection and treatment of diseases. Its stated mission is to develop and deliver innovative nanoparticles that improve the lives of patients around the world, to provide high-quality products and services, and to work with partners to advance the field of nanotechnology. The company also describes applications in regenerative technology and targeted radiological medical imaging. As a private LLC, it does not trade on a public exchange, and detailed financial or ownership information is not publicly disclosed in the available sources.

NanoMedTrix, LLC (NMTx) was created in 2012 as a spin-off of research by Dr. Assouline at the University of Iowa and the National Institutes of Health (NIH), specifically its National Institute of Neurological Disorders and Stroke (NINDS). The company was established with the end goal of producing a clinical-stage oncology and curative enterprise designed to advance the development of a nanoscale particle platform technology. It is based in Coralville, Iowa, in the United States. From its founding, the company's scientific premise has been that engineered nanoparticles can serve simultaneously as imaging contrast agents and as carriers for therapeutic payloads. NanoMedTrix states that its particles are uniquely visible in echo, MRI, CT and by fluorescence, making them ideal for studies of carriers for therapeutic payload to a site of interest. The company describes its platform as multi-modal and targeted, with contrast agents co-crystalized in the particles to enhance the visibility of structures or fluids in the body during scans such as MRI, CT and ultrasound. A central design feature is the intentional void space manufactured within the particles, which allows payloads of diverse bioactive substances to be loaded. Through surface modifications, the targeted particles are intended to impart specificity of the loaded cargo to tumor and cancer cells, so that non-cancerous, normal tissue is inherently spared from the toxicity seen with traditional, systemic treatments. The company also notes that multi-drug options are available for either simultaneous or cascading drug delivery, and that payloads can be targeted for timely release and precise dosage. In oncology, NanoMedTrix reports that its material has been designed to target solid tumors such as bladder, colorectal and neural tumors, and that the same nano-compounds are adjustable to provide valuable information on the disease process of a multitude of illnesses. Bladder cancer is presented as a particular beneficiary of nanotechnology-based treatment because the particles are able to reach muscle-invaded layers. The company has described preclinical testing in mouse, rat and dog models, including an ultrasound (HRS) image of a mouse animal model of bladder cancer in which an inserted tumor was treated with a particle-drug combination and disappeared. Beyond oncology, NanoMedTrix states that its multi-modal, targeted contrast agents are intended for use across a range of disciplines, including regenerative technology and targeted radiological medical imaging. In addition to its core business of nanoparticle development and manufacturing, the company offers a variety of services to the scientific community, including patent-pending multi-scale tools for research into early detection and treatment of diseases. Its stated mission is to develop and deliver innovative nanoparticles that improve the lives of patients around the world, to provide the highest quality products and services, and to work with partners to advance the field of nanotechnology. As a private limited liability company, NanoMedTrix does not disclose public financial statements, and no public listing or large corporate parent is indicated in the available sources.

• 2012

  NanoMedTrix, LLC (NMTx) is created as a spin-off of research by Dr. Assouline at the University of Iowa and NIH/NINDS.

• Company develops multi-modal MSN contrast agents co-crystalized in particles for visibility in echo, MRI, CT and fluorescence.

• Preclinical testing reported in mouse, rat and dog models, including a bladder cancer model in which a particle-drug-treated tumor disappeared.

• Company offers patent-pending multi-scale tools and services to the scientific community for early detection and treatment research.

Developer of multi-modal, targeted theragnostic nanoparticle platforms intended to reduce the time and cost of scientific trials while sparing normal tissue from systemic toxicity.

• MSN multi-modal targeted contrast agents

  Nanoparticles with co-crystalized contrast agents, uniquely visible in echo, MRI, CT and fluorescence, designed to enhance visibility of structures or fluids during scans.

• Targeted nanoparticle drug-delivery platform

  Particles with intentional void space for loading diverse bioactive payloads, surface-modified for specificity to tumor and cancer cells, with multi-drug simultaneous or cascading delivery options.

• Patent-pending multi-scale research tools

  Tools offered to the scientific community for research into early detection and treatment of diseases.

1. 1NanoMedTrix – Small particles, Large Benefitsnanomedtrix.com
2. 2About – NanoMedTrixnanomedtrix.com
3. 3NanoMedTrix – Wikidatawikidata.org